Multidrug resistance-associated biomarkers PGP, GST-π, Topo-II and LRP as prognostic factors in primary ovarian carcinoma

British Journal of Biomedical Science

Volumn 68, Issue 2, 2011, Pages 69-74

  Lu, Dan ^a   Shi, H C ^a   Wang, Z X ^a   Gu, X W ^a   Zeng, Y J ^b  

^a YANGZHOU UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

DNA topoisomerase, type II; Drug resistance, multiple; Glutathione S transferase pi; Lung resistance related protein; Ovarian neoplasms; P Glycoprotein; Prognosis

Indexed keywords

BIOLOGICAL MARKER; DNA TOPOISOMERASE (ATP HYDROLYSING); GLUTATHIONE TRANSFERASE P1; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME;

EID: 79959319213     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2011.11730326     Document Type: Article

References (13)

1. Parker SL, Tong T, Bolden, Wingo PA. Cancer statistics. 1997. CA Cancer J Clin 1997; 47 (1): 5-27. Erratum in CA Cancer J Clin 1997; 47 (2): 68.
2. Guo P, Lu H, Chen YL et al. Clinical significance of multidrug resistance protein expression in non-small cell lung cancer. Sichuan J Cancer Control 2005; 18: 144-7.
3. Cannistra SA. Cancer of the ovary. N Engl J Med 1993; 329 (21): 1550-9. Erratum in N Engl J Med 1994; 330 (6): 448.
4. Yokoyama Y, Sato S, Fukushi Y, Sakamoto T, Futagami M, Saito Y. Significance of multidrug-resistant protein in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res 1999; 25 (6): 387-94. (Pubitemid 30028827)
5. Yin MB, Guo B, Voigt W et al. Novel cellular determination for reversal of multidrug resistance in cells expressing of p170-glycoprotein. Biochim Biophys Acta 1998; 1401 (3): 265-76. (Pubitemid 28122344)
6. Holzamayer TA, Hilsenbeck S, Hoff DD et al. Clinical Correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small cell lung carcinoma. J Natl Cancer Inst 1992; 84 (19): 1468-91.
7. Green JA, Roberton LJ, Clark AH. Glutathione S-transferase expression in benign and malignant ovarian tumours. Br J Cancer 1993; 68 (2): 235-9. (Pubitemid 23229418)
8. Vanhoefer H, Yin MB, Harstrick, Seeber S, Rustum YM. Carbamoylation of glutathione reductase by N,N-bis (2-chloroethyl)-N-nitrosourea associated with inhibition of multidrug resistance protein (MRP) function. Biochem Pharmacol 1997; 53 (6): 801-9. (Pubitemid 27145785)
9. Dang DT, Chen F, Kohli M, Rago C, Cummins JM, Dang LH. Glutathione S-transferase pi1 promotes tumorigenicity in HCT116 human colon cancer cells. Cancer Res 2005; 65 (20): 9485-94. (Pubitemid 41508018)
10. Duca M, Guianvarc'h D, Oussedik K et al. Molecular basis of the targeting of topoisomerase II-mediated DNA cleavage by VP16 derivatives conjugated to triplex-forming oligonucleotides. Nucleic Acids Res 2006; 34 (6): 1900-11.
11. Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C. Topotecan - a novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 1999; 56 (1): 1-12. (Pubitemid 29043890)
12. Dalton WS, Scheper RJ. Lung resistance-related protein: determining its role in multidrug resistance. J Natl Cancer Inst 1999; 91 (19): 1604-5. (Pubitemid 29479928)
13. Arts HJ, Katsaros D, de Vries EG et al. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res 1999; 5 (10): 2798-805. (Pubitemid 29493954)